Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies.
The interferon (IFN) system is a potent line of defense against viral infections. IFN-based agents already tested may be of use in COVID-19 or future viral respiratory outbreaks. Here we review the comparative efficacy, safety/tolerability, and future potential of IFN-based therapeutics. We reviewed...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLOS Global Public Health |
| Online Access: | https://journals.plos.org/globalpublichealth/article/file?id=10.1371/journal.pgph.0000231&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540009318580224 |
|---|---|
| author | Aldina Mesic Emahlea K Jackson Mathias Lalika David M Koelle Rena C Patel |
| author_facet | Aldina Mesic Emahlea K Jackson Mathias Lalika David M Koelle Rena C Patel |
| author_sort | Aldina Mesic |
| collection | DOAJ |
| description | The interferon (IFN) system is a potent line of defense against viral infections. IFN-based agents already tested may be of use in COVID-19 or future viral respiratory outbreaks. Here we review the comparative efficacy, safety/tolerability, and future potential of IFN-based therapeutics. We reviewed human studies in which IFN or IFN pathway-interacting agents were used for viral respiratory infections. We identified 977 articles, of which 194 were included for full-text review. Of these, we deemed 35 articles to be relevant. The use of IFN-based agents for pre-exposure prophylaxis (n = 19) and treatment (n = 15) were most common, with intranasal (n = 22) as the most common route. We found IFN-α (n = 23) was used most often, and rhinovirus (n = 14) was the most common causative agent. Studies demonstrated mixed efficacy but generally positive safety and tolerability. Host-directed therapies, such as IFN or IFN inducers, are worthy of additional research to target viral respiratory infections lacking direct-acting antivirals. |
| format | Article |
| id | doaj-art-edaefbc582cd4975af7a9cff17f0b724 |
| institution | Kabale University |
| issn | 2767-3375 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLOS Global Public Health |
| spelling | doaj-art-edaefbc582cd4975af7a9cff17f0b7242025-02-05T05:50:36ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752022-01-0124e000023110.1371/journal.pgph.0000231Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies.Aldina MesicEmahlea K JacksonMathias LalikaDavid M KoelleRena C PatelThe interferon (IFN) system is a potent line of defense against viral infections. IFN-based agents already tested may be of use in COVID-19 or future viral respiratory outbreaks. Here we review the comparative efficacy, safety/tolerability, and future potential of IFN-based therapeutics. We reviewed human studies in which IFN or IFN pathway-interacting agents were used for viral respiratory infections. We identified 977 articles, of which 194 were included for full-text review. Of these, we deemed 35 articles to be relevant. The use of IFN-based agents for pre-exposure prophylaxis (n = 19) and treatment (n = 15) were most common, with intranasal (n = 22) as the most common route. We found IFN-α (n = 23) was used most often, and rhinovirus (n = 14) was the most common causative agent. Studies demonstrated mixed efficacy but generally positive safety and tolerability. Host-directed therapies, such as IFN or IFN inducers, are worthy of additional research to target viral respiratory infections lacking direct-acting antivirals.https://journals.plos.org/globalpublichealth/article/file?id=10.1371/journal.pgph.0000231&type=printable |
| spellingShingle | Aldina Mesic Emahlea K Jackson Mathias Lalika David M Koelle Rena C Patel Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. PLOS Global Public Health |
| title | Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. |
| title_full | Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. |
| title_fullStr | Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. |
| title_full_unstemmed | Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. |
| title_short | Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. |
| title_sort | interferon based agents for current and future viral respiratory infections a scoping literature review of human studies |
| url | https://journals.plos.org/globalpublichealth/article/file?id=10.1371/journal.pgph.0000231&type=printable |
| work_keys_str_mv | AT aldinamesic interferonbasedagentsforcurrentandfutureviralrespiratoryinfectionsascopingliteraturereviewofhumanstudies AT emahleakjackson interferonbasedagentsforcurrentandfutureviralrespiratoryinfectionsascopingliteraturereviewofhumanstudies AT mathiaslalika interferonbasedagentsforcurrentandfutureviralrespiratoryinfectionsascopingliteraturereviewofhumanstudies AT davidmkoelle interferonbasedagentsforcurrentandfutureviralrespiratoryinfectionsascopingliteraturereviewofhumanstudies AT renacpatel interferonbasedagentsforcurrentandfutureviralrespiratoryinfectionsascopingliteraturereviewofhumanstudies |